ATXS:NSD-Astria Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.22

Change

+0.01 (+0.19)%

Market Cap

USD 0.07B

Volume

0.13M

Avg Analyst Target

USD 13.00 (+149.04%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ATXS Stock Forecast & Price:
Based on the Astria Therapeutics Inc stock forecasts from 1 analysts, the average analyst target price for Astria Therapeutics Inc is USD 13.00 over the next 12 months. Astria Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Astria Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Astria Therapeutics Inc’s stock price was USD 5.22. Astria Therapeutics Inc’s stock price has changed by +28.89% over the past week, +40.32% over the past month and 0% over the last year.

About Astria Therapeutics Inc (ATXS:NSD)

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibi ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+4.88 (+1.66%)

USD73.74B 29.01 20.60
MRNA Moderna Inc

-11.80 (-6.45%)

USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

-8.48 (-1.34%)

USD68.73B 12.65 9.34
BNTX BioNTech SE

-12.09 (-7.14%)

USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

-2.73 (-1.53%)

USD32.89B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.54 (+1.25%)

USD28.69B 41.21 16.21
ALNY Alnylam Pharmaceuticals Inc

-7.37 (-3.19%)

USD27.46B N/A -34.32
GMAB Genmab AS

-0.08 (-0.23%)

USD22.96B 73.23 6.37
BGNE BeiGene Ltd

-4.62 (-2.28%)

USD21.09B N/A -7.47

ETFs Containing ATXS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.15% 79% C+ 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.15% 79% C+ 67% D+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.07B 33% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.24 26% F 22% F
Price / Cash Flow Ratio -2.25 43% F 62% D-
EV/EBITDA -1.00 51% F 64% D
Management Effectiveness  
Return on Equity -32.20% 76% C 31% F
Return on Invested Capital -239.26% 5% F 5% F
Return on Assets -18.92% 69% D+ 22% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.21 76% C 75% C
Short Percent 1.59% 73% C 66% D
Beta 1.59 30% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.